Direct Biologics Announces First Patient Treated Under Phase II Expanded Access Protocol Using ExoFlo™ to Treat COVID-19 The expanded Access Program provides a pathway for patients to gain access to treatment with ExoFlo outside of the active Phase II research clinical trial. AUSTIN, Texas, December 30, 2020 (Newswire.com) Direct Biologics, LLC, announced today that the… Read More »Direct Biologics Announces First Patient Treated Under Phase II Expanded Access Protocol Using ExoFlo™ to Treat COVID-19

The post Direct Biologics Announces First Patient Treated Under Phase II Expanded Access Protocol Using ExoFlo™ to Treat COVID-19 appeared first on Direct Biologics.